Jazz Pharma director withholds 1,706 shares for tax
A Jazz Pharmaceuticals director disposed of shares to cover taxes on vested restricted stock units, not through open-market sales.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Jazz Pharmaceuticals plc (JAZZ) reported insider activity by director Laura Hamill involving dispositions of ordinary shares on August 31, 2026. Two transactions totaling 1,706 shares were delivered or withheld to pay tax obligations arising from the vesting of previously granted restricted stock units, rather than open-market sales. No Rule 10b5-1 trading plan is reported for these transactions.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Ordinary Shares F1 | 14 | $244.0643 | $3K |
| Tax Withholding | Ordinary Shares F1 | 1,692 | $241.39 | $408K |
Footnotes (1)
- F1. Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
Key Figures
Key Terms
restricted stock units financial
Rule 10b5-1 regulatory
tax obligations financial
payment of tax liability by delivering or withholding securities financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did JAZZ director Laura Hamill report?
Were the JAZZ insider transactions open-market sales?
Was a Rule 10b5-1 trading plan involved in these JAZZ transactions?
AI-generated analysis. How Rhea-AI works. Not financial advice.